Compare National Beverage Corp. (FIZZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.89B), while State Street SPDR S&P Biotech ETF trades at $158.16. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | XBI | |
|---|---|---|
Market Cap | $2.89B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $46.75 | $164.28 |
52-Week Low | $30.53 | $86.92 |
Enterprise Value | $2.60B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
